Novavax cuts 2022 revenue guidance in half, stock tanks in after-hours trading

The Maryland biotech company cut its 2022 sales outlook by about 50% and now expects to generate $2 billion to $2.3 billion in revenue this year.

from Health and Science https://ift.tt/vzGhebN
https://ift.tt/8hTBADd
https://ift.tt/K76gaAx